STOCK TITAN
  1. Home
  2. News
  3. NVRO

Nevro Corp - NVRO STOCK NEWS

Welcome to our dedicated news page for Nevro (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nevro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nevro's position in the market.

News
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
Rhea-AI Summary
Nevro Corp. (NVRO) will report its first-quarter 2024 financial results on May 7, 2024, after the market closes. The company, known for its chronic pain treatment solutions, will host an earnings conference call to discuss the results. Investors and analysts can access the live webcast on the company's Investor Relations website. For those without internet access, a conference call option is available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
News
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Rhea-AI Summary
Nevro Corp. announces FDA clearance for Nevro1, a sacroiliac joint fusion device without screws, featuring transfixing technology for long-term fusion. The device includes titanium anchors for stability and 3D-printed bone-growth technology. Positive feedback from orthopedic surgeons and CEO Kevin Thornal highlights its significance in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
clinical trial
-
News
Nevro Enters Into Cooperation Agreement With Engaged Capital
Rhea-AI Summary
Nevro Corp. appoints Kirt P. Karros to its Board of Directors and Audit Committee through a Cooperation Agreement with Engaged Capital, LLC. Mr. Karros, an accomplished finance executive, brings extensive experience in finance, strategic planning, risk management, and mergers and acquisitions. His appointment aims to enhance Nevro's financial management and benefit all stockholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
none
News
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Nevro Corp. reports fourth-quarter and full-year 2023 financial results, provides guidance for 2024, and highlights recent business developments. The company's revenue grew, with a focus on Painful Diabetic Neuropathy (PDN) sales and the acquisition of Vyrsa Technologies™. The restructuring and debt refinancing aim to enhance long-term growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
earnings
-
News
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Rhea-AI Summary
Nevro Corp. has announced the publication of a consensus statement recommending spinal cord stimulation (SCS) therapy for refractory painful diabetic neuropathy (PDN) symptoms. The statement, published in Diabetes Research and Clinical Practice, validates the effectiveness of Nevro HFX for PDN. The company's unique technology behind the 10kHz Therapy offers the greatest efficacy in reducing pain and restoring neurologic function for people with PDN.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
none
-
News
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
Rhea-AI Summary
Nevro Corp. (NVRO) will release its financial results for the fourth quarter and full year ended December 31, 2023, on February 21, 2024. The company will also host a conference call to discuss the results, providing an opportunity for investors to gain insights into the company's performance. The call will be accessible via phone and webcast, offering a comprehensive view of Nevro's financial standing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
conferences earnings
News
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy
Rhea-AI Summary
Nevro Corp. announced that Carelon Healthcare will expand spinal cord stimulation (SCS) coverage for painful diabetic neuropathy (PDN), increasing patient coverage by nearly 43 million lives. This expansion will broaden access to Nevro's 10 kHz Therapy, the only high-frequency parasthesia-free SCS system FDA-approved to treat PDN. The company's approach to expanding payer coverage, combining high-quality clinical trial data and individual case-by-case approvals through patient appeals and external reviews, has been validated by insurance companies. The number of people with diabetes has quadrupled in the last two decades, with PDN affecting up to 25% of them. PDN symptoms can have a significant impact on quality of life, and oral pain medications used to manage this complication have relatively low efficacy and intolerable side effects for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
none
-
News
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting
Rhea-AI Summary
Nevro Corp. presents clinical results of 10 kHz Therapy™ for chronic back and leg pain, non-surgical back pain, and painful diabetic neuropathy at the 2024 North American Neuromodulation Society Annual Meeting. The company will showcase the benefits of HFX iQ™ system and unveil its new sacroiliac joint fusion portfolio. Key presentations include significant reductions in HbA1c, weight, and pain in the treatment of painful diabetic neuropathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
none
-
News
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its preliminary, unaudited fourth-quarter and full-year 2023 revenue results, with worldwide revenue exceeding expectations at $116.0 million for Q4 and $425.0 million for the full year. The company also announced a restructuring, including laying off 5% of its workforce, to support long-term growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
News
Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Nevro Corp. (NYSE: NVRO) announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company's management team will deliver a formal presentation at 8:15 am PST (11:15 am EST). A live webcast and replay of the presentation will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
conferences
Stock NVRO logo
Nevro Corp

NYSE:NVRO

NVRO Rankings

#3026 Ranked by Market Cap
#4959 Ranked by Stock Gains
N/A Ranked by Dividends

NVRO Stock Data

481.54M
35.44M
3.91%
108.64%
11.54%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About NVRO

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.